Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US4939130 | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(11 years ago) | |
US4939130 (Pediatric) | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(11 years ago) | |
US8052987 | SANDOZ | Method of administering bisphosphonates |
Oct, 2023
(6 months ago) | |
US7932241 | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
US7932241 (Pediatric) | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(4 years from now) |
Reclast is owned by Sandoz.
Reclast contains Zoledronic Acid.
Reclast has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Reclast are:
Reclast was authorised for market use on 16 April, 2007.
Reclast is available in injectable;intravenous dosage forms.
Reclast can be used as treatment of osteoporosis in postmenopausal women, treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis.
The generics of Reclast are possible to be released after 05 August, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-595) | May 29, 2012 |
New Indication(I-581) | Dec 19, 2011 |
New Indication(I-584) | Mar 15, 2012 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment of osteoporosis in postmenopausal women; Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS